ROS1 and cholangiocarcinoma: Although aberrant ALK signaling has not been reported in BTC, ROS1 rearrangement and c-MET over-expression have been detected in cholangiocarcinoma; the latter observations are associated with aggressive biological behavior11, 14, 15.